Seer to Report First Quarter 2025 Financial Results on May 13, 2025REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 OutlookValidated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC)
Seer to Participate in the TD Cowen 45th Annual Health Care ConferenceREDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA.
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer’s Proteograph™ Product Suite
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Present at the J.P. Morgan 43rd Annual Healthcare ConferenceREDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA.
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease
Seer to Participate in Upcoming November Investor ConferencesREDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:
Seer Reports Third Quarter 2024 Financial ResultsGrowing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in STAC
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher ScientificCollaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceREDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.
Seer Appoints Nicolas Roelofs to its Board of DirectorsREDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors.
Seer to Participate in the Canaccord Genuity 44th Annual Growth ConferenceREDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA.
Seer Reports Second Quarter 2024 Financial ResultsLaunched STAC in Europe and additional customer papers published in leading journals
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection StudyCombined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects
Seer Reports First Quarter 2024 Financial ResultsDemonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications
Seer to Report First Quarter 2024 Financial Results on May 8, 2024REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Participate in the TD Cowen 44th Annual Health Care ConferenceREDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, MA.
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker DiscoveryStudy led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Present at the J.P. Morgan 42nd Annual Health Care ConferenceREDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services ForumREDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.
Seer Reports Third Quarter 2023 Financial ResultsExpanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence
Seer Announces Addition of Panome Bio to Centers of Excellence (COE) ProgramPanome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services
Seer to Report Third Quarter 2023 Financial Results on November 7, 2023REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter of 2023 after market close on Tuesday, November 7, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Participate in Upcoming September Investor ConferencesREDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:
Seer Reports Second Quarter 2023 Financial ResultsLaunched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies
Seer to Present at the Canaccord Genuity 43rd Annual Growth ConferenceREDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston, MA.
Seer to Report Second Quarter 2023 Financial Results on August 8, 2023REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter of 2023 after market close on Tuesday, August 8, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access CenterExpanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific community to dig deeper into the proteome
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their StudiesSeer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale
Seer Reports First Quarter 2023 Financial ResultsGrew revenue 22% year-over-year with continued growth in installed base
Seer to Report First Quarter 2023 Financial Results on May 9, 2023REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progressionPeptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers
Seer to Present at the Cowen 43rd Annual Health Care ConferenceREDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Cowen 43rd Annual Health Care Conference in Boston, MA.
Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2022, after market close, on Thursday, March 2, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Present at the J.P. Morgan 41st Annual Health Care ConferenceREDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The ScientistAnnual award from The Scientist celebrates transformative products like Seer’s Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible
Seer Reports Third Quarter 2022 Financial ResultsProteograph utility is demonstrated as market interest continues to build with multiple studies underway
Seer to Report Third Quarter 2022 Financial Results on November 8, 2022REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (
NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter of 2022 on Tuesday, November 8, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
